News

The PIM designation is the first step towards inclusion in the Early Access to Medicines Scheme (EAMS).  Launched in April 2014, EAMS offers severely ill patients with life-threatening

The round was led by new investor Versant Ventures. Existing investors New Enterprise Associates, Novo A/S, NanoDimension and Flagship Pioneering also participated. Tarveda plans to use these financial

Milan Zdravkovic, Senior Vice President, Chief Medical Officer, and Head of Research & Development at Sobi, said: “Sobi has a long-term commitment to improve the lives for people

With this expanded capacity, Arven will support local healthcare needs by bringing biopharmaceuticals to the Turkish and surrounding markets faster, whilst also opening up European markets through the

The priority review status will reduce the review clock to six months from the standard 10 months. Even though the action date is not specified, it is expected

After constructive negotiations with several regulators including the US Food and Drug Administration and European Medicines Agency, Summit said it will design a trial intended at assessing the superiority of ridinilazole over the

The first-in-man clinical trial utilizes a single intravenous injection of AAV gene therapy for patients with MPS IIIA (Sanfilippo syndrome type A), a devastating lysosomal storage disease that

This study, which will enroll 40 healthy adults in U.S. sites, follows a successful Phase 1a single ascending dose clinical study completed in 2016. Preclinical studies have shown

The IND is now active and Audentes plans to initiate VALENS, the multicenter, multinational, open-label, ascending dose phase 1 / 2 clinical study of AT342. Preliminary data from